Correlation of low SLC22A18 expression with poor prognosis in patients with glioma
Correlation of low SLC22A18 expression with poor prognosis in patients with glioma
复制标题
胶质瘤患者SLC22A18低表达与不良预后的相关性
DOI：
10.1016/j.jocn.2011.04.032
复制
发表时间：
2012-01-01
影响因子：
2
通讯作者：
Jiang, Pu-Cha
中科院分区：
文献类型：
--
作者：
Chu, Sheng-Hua;Ma, Yan-Bin;Jiang, Pu-Cha
我们研究了假定的肿瘤抑制因子SLC22A18的表达，以评估其作为胶质瘤患者预后标志物的价值。对120例胶质瘤患者的临床组织样本进行免疫组织化学和Western blot分析。SLC22A18在71.7%的患者中低表达。SLC22A18在胶质瘤中的表达缺失与病理分级显著相关（p = 0.003）。高病理分级（World Health Organization III-IV）与SLC22A18的阴性（低表达或缺失）相关，与阳性（高表达）患者相比，SLC22A18的总生存期明显缩短（p = 0.007）。多因素Cox回归分析显示，SLC22A18表达水平是胶质瘤患者生存预后的独立影响因素（p = 0.011）。Western blotting分析证实，与邻近脑组织相比，SLC22A18在胶质瘤组织中的表达降低。这项研究表明，SLC22A18在胶质瘤中发挥肿瘤抑制作用，代表了该疾病长期生存的候选生物标志物。爱思唯尔有限公司版权所有版权所有。
We investigated the expression of the putative tumor suppressor SLC22A18 to evaluate it as a prognostic marker in glioma patients. Immunohistochemical and Western blot analyses of clinical tissue samples obtained from 120 patients with glioma were performed. Low expression of SLC22A18 was observed in 71.7% of patients. Loss of SLC22A18 expression in glioma was significantly related to pathological grade (p = 0.003). High pathological grade (World Health Organization III-IV) was correlated with negative (low or absent) expression of SLC22A18, which was correlated with a significantly shorter overall patient survival than in those with positive (high) expression (p = 0.007). Multivariate Cox regression analysis indicated that SLC22A18 expression level is an independent survival prognostic factor for patients with glioma (p = 0.011). Western blotting analysis confirmed decreased expression of SLC22A18 in glioma tissues compared with adjacent brain tissues. This study suggests that SLC22A18 functions as a tumor suppressor in glioma and represents a candidate biomarker for long-term survival in this disease. Crown Copyright (C) 2011 Published by Elsevier Ltd. All rights reserved.